2022
Post‐treatment effects of topiramate on alcohol‐related outcomes: A combined analysis of two placebo‐controlled trials
Kranzler HR, Feinn R, Pond T, Hartwell E, Gelernter J, Crist RC, Witkiewitz K. Post‐treatment effects of topiramate on alcohol‐related outcomes: A combined analysis of two placebo‐controlled trials. Addiction Biology 2022, 27: e13130. PMID: 35229945, PMCID: PMC9257958, DOI: 10.1111/adb.13130.Peer-Reviewed Original ResearchConceptsAlcohol use disorderPost-treatment periodAlcohol-related outcomesAlcohol-related problemsTopiramate's effectsSingle nucleotide polymorphismsPlacebo-controlled trialPrimary treatment outcomeOptimal treatment durationSelf-reported alcohol consumptionTrial of topiramatePost-treatment effectsTopiramate groupPlacebo groupSecond RCTMedication effectsTreatment outcomesProblematic alcohol useTopiramateTreatment durationUse disordersAlcohol consumptionΓ-glutamyltransferaseRobust effectGenotype groups
2007
Variation in GABRA2 Predicts Drinking Behavior in Project MATCH Subjects
Bauer LO, Covault J, Harel O, Das S, Gelernter J, Anton R, Kranzler HR. Variation in GABRA2 Predicts Drinking Behavior in Project MATCH Subjects. Alcohol Clinical And Experimental Research 2007, 31: 1780-1787. PMID: 17949392, PMCID: PMC3169387, DOI: 10.1111/j.1530-0277.2007.00517.x.Peer-Reviewed Original ResearchConceptsTwelve-step facilitationMotivational enhancement therapyCognitive behavioral therapyPsychosocial treatmentsSingle nucleotide polymorphismsAlcohol dependenceGABRA2 single nucleotide polymorphismsMulti-center randomized clinical trialHeavy drinkingRandomized clinical trialsLow-risk allelesPost-treatment periodPresent studyClinical trialsLower riskEuropean-American subjectsAlcoholism treatmentBehavioral therapyGABRA2 genotypeGABRA2 geneEnhancement therapyLower daily probabilityDrinking outcomesGenetic vulnerabilityPrevious studies